ClinConnect ClinConnect Logo
Search / Trial NCT06697093

Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock

Launched by WROCLAW MEDICAL UNIVERSITY · Nov 19, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Mechanical Circulatory Support Myocardial Infarction Cardiogenic Shock

ClinConnect Summary

The Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock is a clinical trial aimed at understanding how cardiogenic shock is diagnosed and treated in Poland. Cardiogenic shock is a serious condition where the heart can't pump enough blood to meet the body's needs, leading to very low blood pressure and organ problems. The goal of this registry is to gather important information about how often this condition occurs, how patients are treated, and their outcomes. This data will help improve current treatments and establish better support systems for patients who need mechanical help for their heart.

To participate in this study, patients must be over 18 years old and diagnosed with cardiogenic shock, which is a critical state where their blood pressure is very low or they require specific medications to keep their blood pressure up. However, patients who are not breathing on their own or have certain other types of shock will not be included. Those who join the study can expect their health information to be collected over time, which will contribute to better treatment strategies for cardiogenic shock in the future. This initiative is essential because it aims to improve the care and outcomes for patients facing this challenging condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Cardiogenic shock patients of all etiologies in SCAI stage B, C, D, E.
  • age \> 18 years old
  • persistent hemodynamic failure defined as systolic blood pressure of \<90 mmHg for ≥ 30 minutes or the requirement for inotropic or vasopressor agents with evidence of hypoperfusion of the peripheral organs
  • Exclusion Criteria:
  • patients without return of spontaneous circulation who were considered to extracorporeal cardiopulmonary resuscitation (ECPR)
  • primary septic, anaphylactic, hypovolemic shock
  • post-operative cardiogenic shock
  • end-stage of heart failure disqualified from mechanical circulatory support and heart transplantation

About Wroclaw Medical University

Wrocław Medical University is a prestigious academic institution located in Wrocław, Poland, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in healthcare and biomedical sciences to facilitate innovative research initiatives aimed at improving patient outcomes. With a strong emphasis on ethical practices and regulatory compliance, Wrocław Medical University collaborates with a diverse network of healthcare professionals and researchers to conduct rigorous clinical trials that contribute to the development of new therapies and enhance the understanding of various medical conditions. Its dedication to scientific excellence and patient safety positions the university as a key player in the global clinical research landscape.

Locations

Wroclaw, , Poland

Wroclaw, Dolnoslaskie, Poland

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported